根據(jù)發(fā)表在6月18日的Medical Journal of Australia雜志上的一項(xiàng)研究論文的研究作者稱：診斷患有早期乳腺癌的婦女如今可以提供有關(guān)預(yù)后的重要信息,。
十分之一的澳大利亞婦女診斷患有與非轉(zhuǎn)移性乳腺癌，并且預(yù)測(cè)會(huì)在5年內(nèi)發(fā)展轉(zhuǎn)移性疾病。悉尼NHMRC臨床試驗(yàn)中心Sarah Lord表示：但如果癌細(xì)胞已擴(kuò)散到鄰近淋巴結(jié)或鄰近組織，5年內(nèi)發(fā)生轉(zhuǎn)移的風(fēng)險(xiǎn)上升到六分之一。
研究人員研究了新南威爾士州6644名在2001年和2002年間確診患有與非轉(zhuǎn)移性乳腺癌的婦女,，以確定有多少人會(huì)發(fā)展成轉(zhuǎn)移性疾病,。這些婦女與非轉(zhuǎn)移性乳腺癌的婦女分為兩組：局部腫瘤患者（那些腫瘤只局限于乳房組織）和區(qū)域腫瘤患者（那些腫瘤蔓延到區(qū)域淋巴結(jié)或鄰近組織）,。
兩組發(fā)生轉(zhuǎn)移性疾病的整體風(fēng)險(xiǎn)為10％,，但對(duì)于那些局部癌癥患者來(lái)說(shuō),，只有在二十分之一的可能性會(huì)繼續(xù)在5年之內(nèi)發(fā)展成轉(zhuǎn)移性乳腺癌（MBC）。
作者說(shuō)：他們的研究結(jié)果表明除了腫瘤生物學(xué)外,，診斷腫瘤疾病的傳播情況仍然是一個(gè)重要的預(yù)后因素,。臨床醫(yī)師可以使用這些評(píng)估預(yù)后因素告知患有乳腺癌的婦女發(fā)展成MBC的平均風(fēng)險(xiǎn)。（生物谷：Bioon.com）
doi:10.5694/mja12.10026
PMC:
PMID:
Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis
Sarah J Lord, M Luke Marinovich, Jillian A Patterson, Nicholas Wilcken, Belinda E Kiely, Val Gebski, Sally Crossing, David M Roder, Melina Gattellari and Nehmat Houssami
Objectives: To estimate the incidence of metastatic breast cancer (MBC) in Australian women with an initial diagnosis of non-metastatic breast cancer.
Design, setting and participants: A population-based cohort study of all women with non-metastatic breast cancer registered on the New South Wales Central Cancer Register (CCR) in 2001 and 2002 who received care in a NSW hospital.
Main outcome measures: 5-year cumulative incidence of MBC; prognostic factors for MBC.
Results: MBC was recorded within 5 years in 218 of 4137 women with localised node-negative disease (5-year cumulative incidence, 5.3%; 95% CI, 4.6%–6.0%); and 455 of 2507 women with regional disease (5-year cumulative incidence, 18.1%; 95% CI, 16.7%–19.7%). The hazard rate for developing MBC was highest in the second year after the initial diagnosis of breast cancer. Determinants of increased risk of MBC were regional disease at diagnosis, age less than 50 years and living in an area of lower socio-economic status.
Conclusions: Our Australian population-based estimates are valuable when communicating average MBC risks to patients and planning clinical services and trials. Women with node-negative disease have a low risk of developing MBC, consistent with outcomes of adjuvant clinical trials. Regional disease at diagnosis remains an important prognostic factor.
